• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD. ATELLICA IM HBC TOTAL 2 (HBCT2); TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD. ATELLICA IM HBC TOTAL 2 (HBCT2); TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM) Back to Search Results
Model Number N/A
Device Problem False Negative Result (1225)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 11/20/2023
Event Type  malfunction  
Manufacturer Narrative
A customer from outside the united states reported observation of a nonreactive (negative) atellica im hbc total 2 (hbct2) result which was discordant relative to clinical expectation and alternate-method testing.No issues were identified with assay calibration or quality control (qc), and no problems have been seen with other assays.The assay's instructions for use (ifu) states the following, under limitations: "the performance of the assay has not been established for populations of immunocompromised or immunosuppressed patients." "patient samples may contain heterophilic antibodies that could react in immunoassays to give falsely elevated or depressed results.This assay is designed to minimize interference from heterophilic antibodies.Additional information may be required for diagnosis." siemens is investigating.
 
Event Description
The customer reports observation of a nonreactive (negative) atellica im hbc total 2 (hbct2) result which was discordant relative to clinical expectation and alternate-method testing.Hbct2 kit lot 008 was in use at the time.A nonreactive hbct2 result for the affected patient was questioned by laboratory clinicians, and not reported.The laboratory sent the sample for repeat testing at another laboratory, using a different assay method.A conflicting positive result was produced by the alternate method and was accepted as the correct result.There are no allegations of patient harm, changes in treatment, or delays of diagnosis in association with the observed result discordance.
 
Manufacturer Narrative
Mdr 1219913-2023-00324 was initially submitted on 2023-12-12.A customer from outside the united states reported observation of nonreactive (negative) atellica im hbc total 2 (hbct2) results which were discordant relative to clinical expectation and alternate-method testing.No issues were identified with assay calibration or quality control (qc), and no problems had been seen with other assays.While the customer observed several instances of discordant nonreactive results, it is noted that the customer generated >12,000 patient results using hbct2 lot 008, so the observation rate is low.Siemens analysis of customer data showed that the hbct2 positive control result had declined over time, while the lot-008 reagent packs were aboard the instruments.This trend was not observed when the customer used another reagent lot (011).Siemens performed a 7-day on-board stability study in which performance of hbct2 lots 008 and 011 was evaluated with a broad set of samples.Both assay lots met applicable specifications, demonstrating that the product is performing as intended.No product problem was identified.The assay's instructions for use (ifu) states the following, under interpretation of results: "results of this assay should always be interpreted in conjunction with the patient¿s medical history, clinical presentation, and other findings.".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ATELLICA IM HBC TOTAL 2 (HBCT2)
Type of Device
TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM)
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD.
glyn rhonwy, llanberis
caernarfon NY LL554 EL
UK  LL554EL
Manufacturer (Section G)
SIEMENS HEALTHCARE DIAGNOSTICS INC.
333 coney st.
east walpole MA 02032
Manufacturer Contact
barry memishian
333 coney st.
east walpole, MA 02032
5082985306
MDR Report Key18311460
MDR Text Key330945936
Report Number1219913-2023-00324
Device Sequence Number1
Product Code LOM
UDI-Device Identifier00630414604138
UDI-Public00630414604138
Combination Product (y/n)N
Reporter Country CodeTU
PMA/PMN Number
P210019
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 05/10/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberN/A
Device Catalogue Number11200739
Device Lot Number008
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 12/06/2023
Initial Date FDA Received12/12/2023
Supplement Dates Manufacturer Received05/08/2024
Supplement Dates FDA Received05/10/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured01/16/2023
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Age66 YR
Patient SexMale
-
-